{
    "clinical_study": {
        "@rank": "18584", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence"
        }, 
        "brief_title": "A Study of Cabergoline for the Treatment of Cocaine Dependence - 1", 
        "completion_date": {
            "#text": "April 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Cocaine-Related Disorders", 
            "Substance-Related Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cocaine-Related Disorders", 
                "Substance-Related Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with\n      cocaine dependence. This is a DB, placebo-controlled, parallel group design study where\n      subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week\n      follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine\n        dependence; have the ability to understand and provide written informed consent; females\n        of child-bearing potential using proper method of birth control.\n\n        Exclusion Criteria:\n\n        Additional criteria available during screening at the site."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "140", 
        "firstreceived_date": "April 5, 2002", 
        "id_info": {
            "nct_alias": "NCT00024895", 
            "nct_id": "NCT00033111", 
            "org_study_id": "NIDA-CTO-0007-1"
        }, 
        "intervention": {
            "intervention_name": "Cabergoline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cabergoline"
        }, 
        "lastchanged_date": "July 21, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Torrance Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Steve Shoptaw, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "New Use"
            }, 
            {
                "measure": "reduction of severity of cocaine dependence"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00033111"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, Los Angeles", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 2001", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2008"
    }, 
    "geocoordinates": {
        "Medical University of South Carolina": "32.777 -79.931", 
        "Torrance Clinic": "33.836 -118.341"
    }
}